CRUK Cambridge Centre experts and key European stakeholders of the cancer research-prevention-care continuum have teamed up to provide recommendations on how to achieve in 2030 a 10-year cancer-specific survival for 75% of the patients diagnosed in the EU Member states with a well-developed healthcare system.
The annual burden of cancer is expected to increase in the 28 EU member states from 3 million cases in 2018 to around 4 million new cases in 2040.
Over this period, the number of individuals that live with a cancer diagnosis and treatment and require regular screening and specialised care, including rehabilitation and psychological and socio-economic support, will rise even steeper.
With cancer emerging as one of the leading chronic diseases, European healthcare systems are under increasing pressure and will soon be faced with shortage of specialised personnel and resources.
Over the two last decades, the cancer community has explored initiatives that would ensure that all cancer patients will have access to the treatment, care and support they deserve. As a result, the European Commission has recently launched a Cancer Mission, implementing a comprehensive multidisciplinary approach to cancer research to tackle the challenge.
To assist with this endeavour, the European Academy of Cancer Sciences (EACS) has consulted a wide range of cancer research, policy, and care specialists and patient organisations to formulate consensus advice to the Cancer Mission Board. Professor Carlos Caldas who directs our Breast Cancer Programme is a member of the EACS Governing Board.
The findings and recommendations from this consultation have been published this week in the journal Molecular Oncology.
The authors reached the consensus view that a comprehensive translational cancer research approach that is focused on personalised or precision medicine and that covers the entire cancer research, cancer care and prevention continuum has the potential to achieve in 2030 the goal of a 10-year cancer-specific survival for 75% of the patients diagnosed with cancer in EU Member states with a well-developed healthcare system.
The effect of primary prevention on incidence and mortality, however, is viewed as a more long-term goal.
The experts emphasize the need for three sustainable cross-border infrastructures that enable close collaboration of European scientists active in translational research, clinical and prevention trials, and outcomes research. Extensive European networks could provide researchers with access to a critical mass of patients, biological materials and technological resources, bridging research and healthcare.
Furthermore, they provide specific recommendations to prioritise thirteen research areas and offer suggestions as to how to strengthen patients' involvement, improve specialist education, and reduce present inequalities in cancer research within the EU.
The thirteen research areas are: basic and preclinical research; primary prevention; early detection; development of new therapies; rehabilitation; psychosocial oncology; palliative oncology; outcomes research; survivorship research; health economics; paediatric oncology; geriatric oncology; big data and computational science.
Bringing together all relevant stakeholders of the cancer research-prevention-care continuum to speak with a single voice, provide recommendations on careful planning, and inform policy is a pivotal first step towards this ambitious goal.
It will require commitment of policy makers and harmonisation of EU and national priorities to secure the sustainability of the cross-border infrastructures and research networks. Only then, will it be possible to bridge the gaps in science, society and policy, and effectively sustain cancer prevention, treatment, and care across Europe.
Reference
Berns, A. et al Towards a cancer mission in Horizon Europe: recommendations Molecular Oncology August 2020
